

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 050895 AND 051995—Continued

Name of acquiring person, name of acquired person, name acquired entity	PMN No.	Dated terminated
Time Warner Inc., Time Warner Inc., The Music Sound Exchange Company	95-1609	05/15/95
Harbour Group Investments III, L.P., Matthew Warren Group, Inc., Matthew Warren Group, Inc	95-1625	05/15/95
Carlisle Companies Incorporated, Gordon F. Thomsen, Trail King Industries, Inc	95-1569	05/16/95
Imperial Chemical Industries PLC, Grow Group, Inc., Grow Group, Inc	95-1574	05/16/95
Midwest Resources Inc., McLeod Inc., McLeod Inc	95-1583	05/16/95
IES Industries Inc., McLeod, Inc., McLeod, Inc	95-1584	05/16/95
The Sherwin-Williams Company, Grow Group Inc., Grow Group Inc	95-1618	05/16/95
Newell Co., Marshall S. Cogan, CHF Industries, Inc	95-1605	05/17/95
Illinois Tool Works Inc., Foamseal Inc., Foamseal Inc	95-1532	05/18/95
ConAgra, Inc., The Quaker Oats Company, Stokely-Van Camp, Inc	95-1571	05/18/95
Baptist Health Systems of South Florida, Inc., South Miami Health System, Inc., South Miami Hospital, Inc., SMH Homestead Hospital	95-1575	05/18/95
Charterhouse Equity Partners II, L.P., Masada Cable Partners, L.P., Masada Cable Partners, L.P.	95-1596	05/18/95
Coram Healthcare Corporation, Lincare Holdings, Inc., Lincare Holdings, Inc	95-1626	05/18/95

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton,
Contact Representatives, Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room
303, Washington, D.C. 20580, (202) 326-
3100.

By Direction of The Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95-13362 Filed 5-31-95; 8:45 am]

BILLING CODE 6750-01-M

public inspection at 501 School Street
SW., 8th Floor, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT:

White House Conference on Aging, 501
School Street SW., 8th Floor,
Washington, DC 20024; telephone (202)
245-7116.

Dated: May 25, 1995.

Fernando M. Torres-Gil,

Assistant Secretary for Aging.

[FR Doc. 95-13291 Filed 5-31-95; 8:45 am]

BILLING CODE 4130-02-M

inquiries concerning the export of
human biological products under the
Drug Export Amendments Act of 1986
should also be directed to the contact
person.

FOR FURTHER INFORMATION CONTACT:

Cathy Conn, Center for Biologics
Evaluation and Research (HFM-610),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852-
1448, 301-594-2006.

SUPPLEMENTARY INFORMATION: The drug
export provisions in section 802 of the
Federal Food, Drug, and Cosmetic Act
(the act) (21 U.S.C. 382) provide that
FDA may approve applications for the
export of human biological products
that are not currently approved in the
United States. Section 802(b)(3)(B) of
the act sets forth the requirements that
must be met in an application for
approval. Section 802(b)(3)(C) of the act
requires that the agency review the
application within 30 days of its filing
to determine whether the requirements
of section 802(b)(3)(B) have been
satisfied. Section 802(b)(3)(A) of the act
requires that the agency publish a notice
in the **Federal Register** within 10 days
of the filing of an application for export
to facilitate public participation in its
review of the application. To meet this
requirement, the agency is providing
notice that Ortho Diagnostic Systems,
Inc., 1001 US Hwy. 202, Raritan, NJ
08869, has filed an application
requesting approval for the export of the
human biological product Antibody to
Hepatitis B Surface Antigen (human)
ORTHO™ Antibody to HBsAg ELISA
Confirmatory Test to Austria, Belgium,
Canada, Denmark, Federal Republic of
Germany, Finland, France, Iceland,
Ireland, Italy, Japan, Luxembourg, The
Netherlands, New Zealand, Norway,
Portugal, Spain, Sweden, Switzerland,
and The United Kingdom. The Antibody
to Hepatitis B Surface Antigen (human)

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on
Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given,
pursuant to Title II of the Older
Americans Act Amendments of 1987,
Pub. L. 100-175 as amended by Pub. L.
102-375, and Pub. L. 103-171, that the
1995 White House Conference on Aging
Advisory Committee will hold a
meeting on Wednesday, June 14, 1995,
in Washington, DC. The general meeting
will begin at 10:00 a.m. and end at
approximately 12:00 noon. More
specific information on the location for
the meeting can be obtained by calling
the telephone number given below.

The general meeting of the Committee
shall be open to the public. The
proposed agenda includes preparation
of the proposed report of the Conference
which is to be transmitted to the chief
executive officers of the States by
August 3, 1995.

Records shall be kept of all Committee
proceedings and shall be available for

Food and Drug Administration

[Docket No. 95N-0137]

**Drug Export; Antibody to Hepatitis B
Surface Antigen (Human) Ortho™
Antibody to HBsAg Elisa Confirmatory
Test**

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that Ortho Diagnostic Systems, Inc., has
filed an application requesting approval
for the export of the human biological
product Antibody to Hepatitis B Surface
Antigen (human) ORTHO™ Antibody
to HBsAg ELISA Confirmatory Test to
Austria, Belgium, Canada, Denmark,
Federal Republic of Germany, Finland,
France, Iceland, Ireland, Italy, Japan,
Luxembourg, The Netherlands, New
Zealand, Norway, Portugal, Spain,
Sweden, Switzerland, and The United
Kingdom.

ADDRESSES: Relevant information on
this application may be directed to the
Dockets Management Branch (HFA-
305), Food and Drug Administration,
rm. 1-23, 12420 Parklawn Dr.,
Rockville, MD 20857, and to the contact
person identified below. Any future